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Abstract
Background: Recent studies implicate deficiency of red blood cell (RBC) complement regulatory proteins (CR1 and
CD55) in the pathogenesis of malarial anaemia. This study explored the involvement of B cell CD21, which has an
analogous role to RBC CR1.
Methods: In a case control study conducted in Kisumu District hospital, western Kenya, children with severe
malaria anaemia (SMA) and those with uncomplicated malaria (UM) were assessed by flow cytometry for B cells
(CD20+) numbers, expression levels of CD21 and deposition of C3dg and by ELISA for soluble CD21 (sCD21). Paired
t tests were used to determine statistical significance at a = 0.05.
Results: Children with SMA had significantly higher lymphocyte count (9,627.7 ± 8786.1 SD vs. 5,507 ± 2436 SD, P
= 0.04 in the UM group) and the computed geometric mean of mature B-cell numbers based on the absolute
lymphocyte count was significantly higher for SMA group: 1,823 (1,126 to 2,982, 95% CI) and 826.6 (564 to 1,220,
95% CI)] for UM group (P = 0.003). SMA group also had a higher percentage of CD20+ B cells (26.8 ± 9.7SD vs 20.9
± 9.01 SD in the UM) (P=0.03), indicating considerable polyclonal B-cell activation. The CD21 median flourescence
intensity was lower in the SMA (246.4 ± 87.4 SD vs 369 ± 137.7 SD) (P< 0.0001), probably due to complement
mediated shaving of CD21 by fixed tissue macrophages. The CD20+ B cells of SMAs had higher levels of the
complement split product C3dg (18.35 ± 10 SD vs 11.5 ± 6.8 S.D), (P = 0.0002), confirming possible role of
complement in CD21 removal. Unexpectedly, the SMAs had lower levels of sCD21 (226.5 ± 131.5 SD vs 341.4 ±
137.3 SD in the UM) (P < 0.0001), indicating that the shaved CD21 is not released to peripheral circulation.
Conclusions: These results implicate B-cell in pathophysiology of severe malaria that involves increased B-cell
proliferation, increased complement deposition and subsequent loss of membrane-bound CD21. The loss of CD21
is not by the classical enzmatic cleavage.
Background
The global malaria burden remains enormous. Accord-
ing to the World Health Organization (WHO) report of
2008 [1], there were an estimated 247 million malaria
cases and about 3.3 billion people at risk. Malaria has
several manifestations ranging from asymptomatic para-
sitaemia in semi-immune individuals, to severe disease
in susceptible populations that include children below
five years, pregnant women and non-immune adults. In
these individuals, severe malaria manifests in a variety of
forms, including cerebral malaria, severe anaemia, meta-
bolic acidosis, placental malaria and hypoglycaemia,
among others [2,3]. Although these disease patterns
have multiple causes, recent studies implicate acquired
deficiency of RBC complement regulatory proteins such
as CR1 (CD35) and CD55 in pathogenesis of severe
malaria anaemia (SMA) [4,5]. These proteins protect the
RBC from destruction by inhibiting formation of the C3
convertases, thereby preventing the terminal polymeriza-
tion of the membrane attack complex (MAC) [6].
Similar to RBCs, B-cells also bear complement regula-
tory proteins such as CR1 and complement receptor 2
( C R 2 ,C D 2 1 ) .T h e s er e c e p t o r sh a v eb e e ns h o w nt ob e
important in the binding of opsonized IC [7-9]. Studies
with C3b opsonized tetanus toxoid and opsonized
immune complexes have indicated that interaction of
C3 fragments with CD21 allows non-specific B cells to
participate in antigen presentation [10]. Co-ligation of
CD21 with B-cell receptor (BCR) by C3d-taggged anti-
gen also promotes the trafficking of antigen to proces-
sing compartments in the B cell and for more efficient
production of antigenic-peptide/class II complexes [11].
CD21 is only expressed on mature B-lymphocytes [12]
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sion is likely to affect the capacity of B cells to respond
to antigenic stimuli [13,14], the level of expression of
CD21 is tightly controlled. Disease states that alter the
expression of CD21 would, therefore, be expected to
impact the host immunological responses.
Abnormalities of CD21 have been described in various
diseases. In systemic lupus erythematosus (SLE), the
expression level of both CR1 on RBCs [15] and CD21
on B cells is reduced [16]. This decline is usually dis-
ease-mediated and not genetic [17,18]. Reduced expres-
sion of CD21 has also been observed in HIV-sero-
positive individuals. The effect malaria has on the
expression of CD21 and the probable implication has
not been explored.
CD21 also exist in a soluble form (sCD21) that is gen-
erated by shedding of the membrane-associated form
and can be demonstrated in lymphocyte cultures and in
plasma [19-21]. Elevated levels of sCD21 are seen in B-
cell diseases such as chronic lymphocytic leukaemia (B-
CLL) [22], common variable immunodeficiency (CVID),
Brutons’s X-lined gamma-globulinaemia [20,23] and
Epstein-Bar-virus (EBV) malignancies [19].
Although proliferation of B cells is regulated, strong
polyclonal B-cell response resulting in hyper-g-globuli-
naemia and auto-antibodies secretion has been described
in Plasmodium falciparum infections [24]. Studies by
Donati et al. [25] identified the cystein-rich interdomain
region 1 a (CIDR-1 a)o ft h eP. falciparum erythrocyte
membrane protein-1 (PfEMP-1) as responsible for the
polyclonal activation. In this study, the involvement of B
cells during malaria was explored by comparing the B-
cell numbers, levels of complement deposition, levels of
m e m b r a n eb o u n da n ds C D 2 1i ng r o u p so fc h i l d r e nw i t h
either severe or uncomplicated malaria.
Methods
This study was a hospital-based prospective case-control
and details of the study, including ethical approvals,
have been described previously [26].
Determination of CD20+ cell population, expression level
of CD21 and C3dg deposition
A5 0μL aliquot of each EDTA blood sample was placed
into three wells (test sample, unstained control and isotype
control) of a round-bottom, 96-well plate. To each well
was added 200 μL of wash buffer (PBS containing 1% BSA
and 0.1% sodium Azide). The re-suspended cells were cen-
trifuged for three minutes at a 1,620xg and the supernatant
discarded. Thereafter, the cell pellet was re-suspended in
100 μL of 10% mouse IgG in PBS and then incubated for
30 minutes at room temperature. This was followed by
three washes and the cell pellet re-suspended in 100 μLo f
antibody cocktail comprising CD20PerCP (BD Pharmigen,
USA)/CD21PE (BD Pharmigen, USA)/C3dgAL488 (a gift
from Prof. Ronald P Taylor, University of Virginia, Char-
lottesville, USA) at a final concentration of 1 μg/mL and
mouse IgG1-k for isotype control well. For the unstained
control, wash buffer was added followed by incubation for
30 minutes at 4°C. Thereafter, the cells were washed and
the cell pellet re-suspended in 200 μL of lysing buffer (150
mM NH4Cl, 10 mM NaHCO3 and 1 mM EDTA) for three
minutes at room temperature, then washed twice. Finally,
the cells were re-suspended in 100 μLo f1 %P a r a f o r m a l d e -
hyde and stored at 4°C until acquisition (within 24 hours
after staining).
Following staining, data acquisition was done on a Bec-
ton Dickson FACScan (BD, San Jose, CA, USA) with
WinFCM (Phoenix Flow systems, San Francisco USA) as
the acquisition software. Lymphocytes were gated based
on FSC and SSC and 20,000 events were acquired. Analy-
sis was done using EXPO software (Phoenix Flow sys-
tems, San Francisco USA). Expression level for CD21 and
C3dg deposition were reported as median fluorescence.
Quantification of sCD21 by ELISA
Commercially available enzyme immunoassay kits for
sCD21 (Cellsciences, Massachusetts, USA) was used.
Plates were supplied pre-coated with a monoclonal anti-
body specific for CD21. 100 μL of serially diluted stan-
dards with concentrations that ranged from 3.12-100
units/mL and 100 μL of plasma samples diluted 1:4 were
added to their respective wells followed by the addition
of 50 μL of a biotinylated monoclonal antibody specific
for CD21 to each well and incubated for one hour at 25°
C. At the end of the incubation, the wells were washed
t w i c eb ya d d i n g3 0 0μL of the wash buffer to each well
and aspirating. Thereafter, 100 μL of streptavidin-HRP
was added to each well followed by 30 minutes incuba-
tion at room temperature. Unbound enzyme was
removed and wells washed by adding and aspirating 300
μL of the wash buffer. 100 μL of ready-to-use 3,3’,5 , 5 " -
tetramethylbenzidine (TMB) substrate solution was
added to each well and incubated at room temperature
for 20 minutes in the dark. The reaction was stopped by
the addition of 100 μL of 0.16 M sulfuric acid and colour
intensity read at 415 nm using the VMax
® Kinetic ELISA
Microplate Reader (Molecular devices, CA, USA). The
concentration of the sCD1 in the samples was deter-
mined by extrapolating from the standard curve.
Statistical analysis was done using Graphad
® Prism
software Version 5 (CA, USA). 2 tailed paired t-tests
were performed with the level of significance set at 0.05.
Results
Demographics and clinical data
The demographics and clinical data for the study parti-
cipants is shown in Table 1. There was no difference in
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Although the SMA group had a higher parasite density
[Geometric mean (95% CI)], 33295 (19191-57764) than
the UM group 22196 (10387-47432), the difference was
not significant. The absolute lymphocyte count was sig-
nificantly higher for the SMA group 9628 ± 8786 as
compared to the UM group 5507 ± 2436 (P = 0.039).
Mature B-cell population, expression level of CD21 and
C3dg deposition in severe and uncomplicated malaria
Lymphocytes were identified on the basis of their for-
ward scatter (FSC) and side scatter (SSC) characteristics.
As shown in Table 1, absolute lymphocyte count was
significantly higher in the SMA group (9628 ± 8786 SD)
compared to the UM group (5,507 ± 2436 SD, P = 0.04).
Figure 1, panel A shows the percentage CD20+ B cells
in the two study groups. SMA had a higher mean per-
centage CD20+ cells (26.8 ± 9.7 SD) compared to the
UM group (20.9 ± 9.1 SD, P = 0.03) and as shown in
Figure 1, panel B, the computed geometric mean num-
bers of these mature B-cells based on the absolute lym-
phocyte count was 1,823 (1,126 to 2,982, 95% CI) for
SMA and 826.6 (564 to 1,220, 95% CI)] for UM group
(P = 0.003).
Figure 1, panel C shows that the SMA group had a
statistically significant lower CD21 median fluorescence
intensity (246.4 ± 87.4 SD) compared to the UM con-
trols (369 ± 137.7 SD) (P < 0.0001). Thus although the
SMA group had elevated numbers of mature B cells,
their expression of membrane-bound CD21 was
reduced. Lastly, as shown in Figure 1, panel D, SMAs
had a higher percentage of C3dg bearing CD20+ B cells
(18.35 ± 10 S.D) compared to UM control (11.5 ± 6.8
SD, P = 0.0002).
Levels of plasma sCD21 in severe and uncomplicated
malaria
Plasma sCD21 was lower in SMA (246.4 ± 87.4 SD
units/mL) compared to the UM controls (341.4 ± 137.3
SD, P < 0.0001) (Figure 2).
Discussion
Previous studies on the pathogenesis of malarial anae-
mia have focused on the role of RBC complement
regulatory proteins on the pathophysiology of severe
malaria and have shown a marked reduction of CR1,
increased deposition of complement products and
increased consumption of complement in children with
malarial anaemia [5,27]. Like RBC, B cell is involved in
complement processing and has molecules such as
CD21, also known as complement receptor 2 (CR2) that
share many structural and functional characteristics
with RBC CR1. The current study evaluated the effect
malaria has on complement regulatory role of B cell.
As has been shown in previous studies [2,3], parasite
density cannot be the key cause to severe anaemia, as
the parasitaemia for children in the UM group did not
differ from those with severe anaemia (Table 1). Chil-
dren with SMA had increased levels of CD20+ B cells as
compared to the UM (Figure 1A), with the B-computed
absolute B-cell being also higher in the SMA group (Fig-
ure 1B). This expansion in B-cell population is in agree-
ment with previous findings that have shown that B-cell
population is increased during malaria [28] leading to
strong polyclonal B-cell response and subsequent hyper-
globulinaemia [29]. The cystein-rich inter-domain region
1a (CIDR1a) of the PfEMP1 has been incriminated as
being the ligand that interacts with B cells to cause pro-
liferation and activation [25].
A m o n gt h em a n yr o l e so fC D 2 1i st ob i n dt h ec o m -
plement split fragment C3dg [30], thus, like RBC CR1,
mops up circulating complement products for removal
by the reticuloendothelial macrophages. The removal of
C3dg by macrophages inadvertently leads to shaving off
of CD21 molecules, in a manner analogous to removal
of RBC CR1 [31]. As shown in Figure 1C, children with
SMA had lower CD21 MFI compared to those with
UM. Although the mature B cells were more in SMA
than in the UM, the mean level of expression of CD21
was lower (Figure 1C). Reduced CD21 expression has
been reported in other diseases such as in SLE, an auto-
immune disorder associated with increased levels of cir-
culating immune-complexes [16] and in HIV sero-
positive individuals [32]. Reduced expression of CD21
may have implications in the mounting of a sufficient
immune response since CD21 has been shown to pro-
mote the expression of B-cell receptor (BCR) signalling
through the formation of CD19/CD21 complex [33],
Table 1 Demographics and clinical data of the study participants
Characteristic Severe Anaemia Uncomplicated Malaria P value
Sample size (N) 30 30
Age (months) (Mean ± SD) 16.67 ± 9.217 17.02 ± 9.5 NS
Parasitaemia [Geo mean (95% CI)] 33295 (19191-57764) 22196 (10387-47432) NS
Hb level (g/dl, mean ± SD) 4.5 ± 1.0 8.9 ± 1.3 ND
Absolute lymphocyte count/L (mean ± S.D) 9628 ± 8786 5507.82 ± 2436 0.04
NS- Not significant, ND- Not done since Hb level was one of the recruitment criteria for SMA cases
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humoral response.
Contrary to expectation and as shown in Figure 2, the
mean sCD21 was significantly lower in children with
SMA compared to UM controls. The expectation would
have been that the loss of membrane bound CD21 is by
enzymatic cleavage and thus would end up in plasma as
sCD21 [34]. The data reported here does not support
the enzymatic cleavage assumption, but rather gives cre-
dence to the shaving hypothesis which proposes that the
accelerated loss of membrane bound CD21 occurs in
the reticuloendothelial system during the removal of
opsonized ICs [32]. Like malaria, the other diseases that
are characterized by immune-complex formation such
as juvenile arthritis, SLE and Sjögren’s syndrome, have
reduced levels of sCD21 [35,36]. sCD21 retains the
capacity to bind iC3b and CD23 [37], and the reduced
levels may thus impair responses that are mediated by
these ligands.
C3dg is a downstream product of the complement
activation and can be used as a surrogate measure of
complement activation. As shown in Figure 1D, children
in the SMA group had an increased deposition of C3dg
on the surface of B cells compared to the UM group.
Increased C3dg deposition is a pointer to increased
complement activation during SMA. Because it is the
deposition of complement product that mediate interac-
tion of B cell with the macrophages, the increased
deposition of complement product in SMAs is responsi-
ble for shaving of CD21 [38].
Conclusions
Results from this study show B-cell involvement in the
immunopathology of severe malaria anaemia, mainly
Figure 1 % CD20, absolute cell count, CD21 expression level and C3dg deposition in children with severe (SMA) and uncomplicated
malaria (UM). Panel A: Children with SMA had a higher % of CD20+ B cells compared to UM group (P = 0.03). Panel B: Computed absolute B-
cell values were higher in children with SMA compared to those with UM (P = 0.003). Panel C: The median fluorescent intensity of CD21 was
lower in children with SMA compared to the UM controls (P < 0.0001). Panel D: B cells of SMA children had a higher percentage of C3dg
deposited on their surfaces compared to those in the UM group (P = 0.0002).
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tion of C3dg and the loss of both membrane bound and
soluble CD21. Interestingly, the loss of membrane-
bound CD21 is not through the classical enzymatic clea-
vage, but probably involves interaction of CD21 loaded
with C3dg with cells of reticuloendothelial system, in a
manner analogous to removal of C3b bearing CR1 on
red blood cells.
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